Long Term Characteristics of Clinical Distribution and Resistance Trends of Carbapenem-Resistant and Extended-Spectrum β-Lactamase Klebsiella pneumoniae Infections: 2014–2022

References

• Raffelsberger N, Hetland MAK, Svendsen K, et al. Gastrointestinal carriage of Klebsiella pneumoniae in a general adult population: a cross-sectional study of risk factors and bacterial genomic diversity. Gut Microbes. 2021;13(1):1939599. doi:10.1080/19490976.2021.1939599
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/s1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66. doi:10.1016/s1473-3099(18)30605-4
   PubMed Web of Science ®Google Scholar
• Antimicrobial TECo. Clinical breakpoints - breakpoints and guidance; 2022. Available from: https://wwweucastorg/clinical_breakpoints. Accessed January 1, 2022.
   Google Scholar
• Chinet Thwcc. Variation of resistance of Klebsiella pneumoniae to imipenem and meropenem; 2022. Available from: http://wwwchinetscom/Data/GermYear. Accessed February 27, 2023.
   Google Scholar
• Murray CJ, Ikuta KS, Sharara F, et al.Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/s0140-6736(21)02724-0
   PubMed Web of Science ®Google Scholar
• Issakhanian L, Behzadi P. Antimicrobial Agents and Urinary Tract Infections. Curr Pharm Des. 2019;25(12):1409–1423. doi:10.2174/1381612825999190619130216
   PubMed Web of Science ®Google Scholar
• Ernst CM, Braxton JR, Rodriguez-Osorio CA, et al. Adaptive evolution of virulence and persistence in carbapenem-resistant Klebsiella pneumoniae. Nat Med. 2020;26(5):705–711. doi:10.1038/s41591-020-0825-4
   PubMed Web of Science ®Google Scholar
• Agyeman AA, Bergen PJ, Rao GG, Nation RL, Landersdorfer CB. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833. doi:10.1016/j.ijantimicag.2019.10.014
   PubMed Web of Science ®Google Scholar
• Ramos-Castañeda JA, Ruano-Ravina A, Barbosa-Lorenzo R, et al. Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections. J Infect. 2018;76(5):438–448. doi:10.1016/j.jinf.2018.02.007
   PubMed Web of Science ®Google Scholar
• Behzadi P, García-Perdomo HA, Karpiński TM, Issakhanian L. Metallo-ß-lactamases: a review. Mol Biol Rep. 2020;47(8):6281–6294. doi:10.1007/s11033-020-05651-9
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Ranjbar R, Behzadi P, Mohammadian T. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella Pneumoniae. Expert Rev Anti Infect Ther. 2022;20(3):463–472. doi:10.1080/14787210.2022.1990040
   PubMed Web of Science ®Google Scholar
• Shen S, Shi Q, Hu F. The changing face of Klebsiella pneumoniae carbapenemase: in-vivo mutation in patient with chest infection. Lancet. 2022;399(10342):2226. doi:10.1016/s0140-6736(22)01011-x
   PubMed Web of Science ®Google Scholar
• Jean SS, Hsueh PR. Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother. 2017;72(1):166–171. doi:10.1093/jac/dkw398
   PubMed Web of Science ®Google Scholar
• Almomani BA, Hayajneh WA, Ayoub AM, Ababneh MA, Al Momani MA. Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study. Infection. 2018;46(4):495–501. doi:10.1007/s15010-018-1148-y
   PubMed Web of Science ®Google Scholar
• CARS. 2020 national bacterial resistance surveillance report (abbreviated version); 2022. Available from: http://wwwcarsscn/Report/Details?aId=808. Accessed November 17, 2021.
   Google Scholar
• Hu Y, Liu C, Shen Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018. Emerg Microbes Infect. 2020;9(1):1771–1779. doi:10.1080/22221751.2020.1799721
   PubMed Web of Science ®Google Scholar
• Magill SS, O’Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732–1744. doi:10.1056/NEJMoa1801550
   PubMed Web of Science ®Google Scholar
• Chew KL, Lin RTP, Teo JWP. Klebsiella pneumoniae in Singapore: hypervirulent infections and the carbapenemase threat. Front Cell Infect Microbiol. 2017;7:515. doi:10.3389/fcimb.2017.00515
   PubMed Web of Science ®Google Scholar
• Li G, Zhao S, Wang S, Sun Y, Zhou Y, Pan X. A 7-year surveillance of the drug resistance in Klebsiella pneumoniae from a primary health care center. Ann Clin Microbiol Antimicrob. 2019;18(1):34. doi:10.1186/s12941-019-0335-8
   PubMed Web of Science ®Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med. 2020;382(14):1309–1319. doi:10.1056/NEJMoa1914433
   PubMed Web of Science ®Google Scholar
• Jia X, Li C, Chen F, et al. Genomic epidemiology study of Klebsiella pneumoniae causing bloodstream infections in China. Clin Transl Med. 2021;11(11):e624. doi:10.1002/ctm2.624
   PubMed Web of Science ®Google Scholar
• Wang N, Zhan M, Liu J, et al. Prevalence of carbapenem-resistant Klebsiella pneumoniae infection in a Northern Province in China: clinical characteristics, drug resistance, and geographic distribution. Infect Drug Resist. 2022;15:569–579. doi:10.2147/idr.S347343
   PubMed Web of Science ®Google Scholar
• Tian L, Tan R, Chen Y, et al. Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality. Antimicrob Resist Infect Control. 2016;5:48. doi:10.1186/s13756-016-0145-0
   PubMed Web of Science ®Google Scholar
• Richet H. Seasonality in Gram-negative and healthcare-associated infections. Clin Microbiol Infect. 2012;18(10):934–940. doi:10.1111/j.1469-0691.2012.03954.x
   PubMed Web of Science ®Google Scholar
• Kaier K, Frank U, Conrad A, Meyer E. Seasonal and ascending trends in the incidence of carriage of extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella species in 2 German hospitals. Infect Control Hosp Epidemiol. 2010;31(11):1154–1159. doi:10.1086/656748
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Zampino R. Management of carbapenem-resistant Enterobacteriaceae infections. Clin Microbiol Infect. 2019;25(8):943–950. doi:10.1016/j.cmi.2019.04.013
   PubMed Web of Science ®Google Scholar
• Medeiros GS, Rigatto MH, Falci DR, Zavascki AP. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents. 2019;53(2):152–157. doi:10.1016/j.ijantimicag.2018.10.010
   PubMed Web of Science ®Google Scholar
• Quan J, Li X, Chen Y, et al. Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae recovered from bloodstream infections in China: a multicentre longitudinal study. Lancet Infect Dis. 2017;17(4):400–410. doi:10.1016/s1473-3099(16)30528-x
   PubMed Web of Science ®Google Scholar
• Butler DA, Rana AP, Krapp F, et al. Optimizing aminoglycoside selection for KPC-producing Klebsiella pneumoniae with the aminoglycoside-modifying enzyme (AME) gene aac(6’)-Ib. J Antimicrob Chemother. 2021;76(3):671–679. doi:10.1093/jac/dkaa480
   PubMed Web of Science ®Google Scholar
• Ahmadi Z, Noormohammadi Z, Behzadi P, Ranjbar R. Molecular detection of gyrA mutation in clinical strains of Klebsiella pneumoniae. Iran J Public Health. 2022;51(10):2334–2339. doi:10.18502/ijph.v51i10.10992
   PubMed Web of Science ®Google Scholar
• To KK, Lo WU, Chan JF, Tse H, Cheng VC, Ho PL. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect Dis. 2013;17(2):e120–4. doi:10.1016/j.ijid.2012.09.008
   PubMed Web of Science ®Google Scholar
• Sharara SL, Amoah J, Pana ZD, Simner PJ, Cosgrove SE, Tamma PD. Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing organisms? Clin Infect Dis. 2020;71(8):e331–e337. doi:10.1093/cid/ciz1205
   PubMed Web of Science ®Google Scholar
• Gould M, Ginn AN, Marriott D, Norris R, Sandaradura I. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae. Int J Antimicrob Agents. 2019;54(2):240–244. doi:10.1016/j.ijantimicag.2019.05.013
   PubMed Web of Science ®Google Scholar
• Lu J, Qing Y, Dong N, et al. Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria. Saudi Pharm J. 2022;30(6):849–855. doi:10.1016/j.jsps.2022.03.007
   PubMed Web of Science ®Google Scholar
• Piedra-Carrasco N, Miguel L, Fàbrega A, et al. Effectiveness of a double-carbapenem regimen in a KPC-producing Klebsiella pneumoniae infection in an immunocompromised patient. Microb Drug Resist. 2018;24(2):199–202. doi:10.1089/mdr.2017.0129
   PubMed Web of Science ®Google Scholar
• Ahmadi Z, Noormohammadi Z, Ranjbar R, Behzadi P. Prevalence of Tetracycline Resistance Genes tet (A, B, C, 39) in Klebsiella pneumoniae isolated from Tehran, Iran. Iran J Med Microbiol. 2022;16(2):141–147. doi:10.30699/ijmm.16.2.141
   Google Scholar
• Jorba M, Pedrola M, Ghashghaei O, et al. New trimethoprim-like molecules: bacteriological evaluation and insights into their action. Antibiotics. 2021;10(6):709. doi:10.3390/antibiotics10060709
   Google Scholar
• Sarshar M, Behzadi P, Ambrosi C, Zagaglia C, Palamara AT, Scribano D. FimH and anti-adhesive therapeutics: a disarming strategy against uropathogens. Antibiotics. 2020;9(7):397. doi:10.3390/antibiotics9070397
   Web of Science ®Google Scholar
• Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol. 2019;17(5):295–306. doi:10.1038/s41579-019-0159-8
   PubMed Web of Science ®Google Scholar